In the past, we used to make our Monthly Script newsletters freely available on-line. However, a decision was taken a few months ago to start restricting access to this newsletter (and to some of our other materials) to only our subscriber CCGs, i.e. those CCGs that currently commission our medicines optimisation services.
Consequently, our blog has been a bit quiet recently!!!!!!
To address this, we have decided that we will start sharing a list of items that we have included in the most recent Monthly Script, which, we hope, may still be of interest to some readers. This list includes links to new guidance, safety updates, news items and evidence that the team at Keele has decided to highlight to our CCGs.
Below is the list for the June Monthly Script newsletter (The eagle-eyed may spot that the new atrial fibrillation guidance from NICE is not included, as this came out after we put this list together!).
We hope you find it useful!
The Keele Medicines Optimisation Team
Keele’s June Monthly Script content
Update from NICE:
- Medicines and Prescribing Centre’s evidence summary of dapoxetine for erectile dysfunction
- · New NICE public health guideline: Overweight and obese adults - lifestyle weight management (PH53)
- · MHRA update: Adrenaline auto-injector advice for patients: after every use, an ambulance should be called even if symptoms are improving, the individual should lie down with legs raised and, if at all possible, should not be left alone
- · MHRA update: Domperidone: risks of cardiac side effects— indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use (also link to Trent MI publication
- · MHRA’s review of Statins - benefits and risks
- · MHRA’s final advice on Zolpidem: risk of drowsiness and reduced driving ability
- · FDA’s drug safety communication on Pradaxa (dabigatran): Lower Risk for Stroke and Death, but Higher Risk for GI Bleeding Compared to Warfarin
- · EU starts review of hydroxyzine-containing medicines
- · EU starts review of ivabradine (Procoralan)
National policy and guidance:
Update on UKMI publications:
- · Is melatonin effective for preventing cluster headache?
- · Is there an interaction between erythromycin and statins?
- · What is the available evidence for the use of statins in patients with renal impairment?
- · Which medicines can be used to treat intermittent allergic rhinitis during pregnancy?
- · Chondroitin – what are the adverse effects?
- · Does St John’s Wort interact with Emergency Hormonal Contraception?
- · Is there an interaction between St John’s Wort and combined and progestogen only hormonal contraceptives?
- · NICE Bites on Managing Meds in Care Homes
- New Public Health England resources for CCGs: ‘Commissioning for value packs’ to improve cardiovascular services
- · Changes to the legal classifications of tramadol, lisdexamfetamine, zopiclone and zaleplon
- · Report: Why asthma still kills
- · New product: Vitaros (alprostadil) 3 mg/g cream for ED
On the horizon:
- · European Commission approves empagliflozin (Jardiance®) for type 2 diabetes
- · European CHMP recommends approval of dexamfetamine sulphate (Dexamed®) for the second-line treatment of ADHD
- · Anoro® (umeclidinium/vilanterol) approved in EU for treatment Of COPD